Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2020, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.
Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 3, 23, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.
Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Post-Traumatic Stress Disorder (PTSD) - Overview
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aision Biotechnologies Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Armgo Pharma Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Avicanna Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cannabis Science Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by EpiVario Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Kdac Therapeutics Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroRx Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurovation Labs Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by One World Cannabis Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Quoin Pharmaceuticals Ltd, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Scientus Pharma Inc, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Seelos Therapeutics, Inc., H1 2020
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2020
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned
Actinogen Medical Ltd
Addex Therapeutics Ltd
Aision Biotechnologies Inc
Amorsa Therapeutics Inc
Anagin Inc
Aptinyx Inc
Armgo Pharma Inc
Artelo Biosciences Inc
Avicanna Inc
Azevan Pharmaceuticals Inc
Bionomics Ltd
Cannabis Science Inc
Catalyst Pharmaceuticals Inc
Chronos Therapeutics Ltd
Corcept Therapeutics Inc
Eli Lilly and Co
Embera NeuroTherapeutics Inc
EpiVario Inc
HolsboerMaschmeyer NeuroChemie GmbH
Immodulon Therapeutics Ltd
INVENT Pharmaceuticals Inc
Johnson & Johnson
Kdac Therapeutics Inc
Lixte Biotechnology Holdings Inc
NeuroNascent Inc
NeuroRx Inc
Neurovation Labs Inc
Omeros Corp
One World Cannabis Ltd
Otsuka Holdings Co Ltd
Quoin Pharmaceuticals Ltd
Sanofi
Scientus Pharma Inc
Seelos Therapeutics, Inc.
Tonix Pharmaceuticals Holding Corp
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets